SEC Tracker
Get the app
GALT · XBRL financial data

Galectin Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GALT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development7,7328,228*8,0549,8137,59511,109*6,4853,2612,6111,933*2,2312,135
General and administrative1,4341,333*1,5941,4781,4711,319*1,4121,3641,5871,432*1,8461,847
Total operating expenses9,1669,561*9,64811,2919,06612,428*7,8974,6254,1983,365*4,0773,982
Operating income (loss)(9,166)(9,561)*(9,648)(11,291)(9,066)(12,428)*(7,897)(4,625)(4,198)(3,365)*(4,077)(3,982)
Interest income6274*80809384*35263925*3628
Interest expense835847*1,0521,2691,4941,725*1,7441,8261,8201,939*1,9882,004
Income tax expense (benefit)—————year only———year only——
Net income (loss)(10,428)(9,997)*(11,489)(12,371)(11,220)(11,967)*(9,631)(7,521)(8,184)(5,500)*(5,046)(9,113)
Earnings per share, basic USD per share(0.24)(0.16)*(0.19)(0.20)(0.18)(0.19)*(0.15)(0.12)(0.13)(0.08)*(0.08)(0.14)
Earnings per share, diluted USD per share(0.24)(0.16)*(0.19)(0.20)(0.18)(0.19)*(0.15)(0.12)(0.13)(0.08)*(0.08)(0.14)
Weighted average shares, basic thousands of shares59,70461,849*61,97662,23362,27862,745*63,20463,44764,20564,736*65,78265,875
Weighted average shares, diluted thousands of shares59,70461,849*61,97662,23362,27862,745*63,20463,44764,20564,736*65,78265,875

Balance sheet

CSV

Fiscal quarters (GALT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents20,36225,66023,55525,59827,06015,1207,43113,77111,52517,72014,11113,269
Prepaid and other current assets1,2492,0501,9051,6891,6062,1321,8541,6561,2041,7161,5801,390
Total current assets21,61127,71025,46027,28728,66617,2529,28515,42712,72919,43615,69114,659
Property and equipment, net—0———0———0——
Right-of-use asset625345352616665237226118
Total assets22,16328,20025,89027,65528,97217,4959,52815,60212,86519,53215,75914,826
Accounts payable2,6816,4313,7973,6982,7955,6566,5345,8655,3903,2453,1213,727
Accrued liabilities7,8419,1828,83610,85611,5868,2046,8954,8465,0384,7224,1863,993
Total current liabilities10,52215,67612,63314,61725,25835,409110,84010,774136,4458,0307,307151,619
Lease liability, non-current32207—————————
Total liabilities73,03688,44196,976109,802121,453120,565121,789132,769136,445145,727145,996151,678
Accumulated deficit(344,312)(354,372)(365,869)(378,304)(389,542)(401,572)(411,177)(418,761)(426,984)(432,546)(437,613)(446,788)
Total stockholders' equity(52,596)(61,964)(72,809)(83,870)(94,204)(104,793)(113,984)(118,890)(125,303)(127,918)(131,960)(138,575)
Total liabilities and equity22,16328,20025,89027,65528,97217,4959,52815,60212,86519,53215,75914,826
Common shares outstanding (cover page) thousands of shares61,84961,90462,14862,27862,76263,18063,29264,06064,47365,82765,857100,850

Cash flows

CSV

Fiscal quarters (GALT's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(10,428)(9,997)*(11,489)(12,371)(11,220)(11,967)*(9,631)(7,521)(8,184)(5,500)*(5,046)(9,113)
Stock-based compensation586*497*604738*515*590*468500*496*195*686963*
Net cash from operating activities(7,637)*(4,702)*(12,105)(8,333)*(8,538)*(12,791)*(7,689)(6,602)*(3,542)*(6,042)*(3,866)(2,439)*
Net cash from investing activities—year only———year only———year only——
Proceeds from issuing common stock————0*0*——853*1,164*——
Net cash from financing activities10,033*10,000*10,00010,376*10,000*851*012,942*1,296*12,237*2571,597*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Galectin Therapeutics13,269not reported(2,439)*100.8M5.4 quarters 10-QJun 30, 2026
Cartesian Therapeutics147,6060(21,082)*30.3M7.0 quarters 10-QJun 30, 2026
Enanta Pharmaceuticals33,41914,359(9,972)*29.1M19.0 quarters 10-QJun 30, 2026
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026
TuHURA Biosciences996not reported(8,634)*63.7M0.1 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41,24917,87450*35.1M— 10-QJun 30, 2026
Protara Therapeutics17,076not reported(15,389)*59.1M9.3 quarters 10-QJun 30, 2026
Caribou Biosciences26,1941,499(22,787)*107.2M4.9 quarters 10-QJun 30, 2026
Fate Therapeutics32,4292,082(23,400)119.8M6.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.